Ubs Group Ag Amphastar Pharmaceuticals, Inc. Transaction History

Ubs Group Ag

$527 Billion
Q4 2024

A detailed history of Ubs Group Ag transactions in Amphastar Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 153,742 shares of AMPH stock, worth $4.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

153,742

Previous 101,032 52.17%

Holding current value

$4.2 Million

Previous $4.9 Million 16.42%

% of portfolio

0.0%

Previous 0.0%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$36.84 - $53.4 $1.94 Million - $2.81 Million	52,710 Added 52.17%	153,742 $5.71 Million
Q3 2024 Nov 14, 2024	SELL	$36.99 - $50.09 $800,796 - $1.08 Million	-21,649 Reduced 17.65%	101,032 $4.9 Million
Q2 2024 Aug 13, 2024	BUY	$38.65 - $43.48 $1.63 Million - $1.84 Million	42,229 Added 52.49%	122,681 $4.91 Million
Q1 2024 May 13, 2024	BUY	$42.85 - $63.45 $401,333 - $594,272	9,366 Added 13.18%	80,452 $3.53 Million
Q4 2023 Feb 09, 2024	BUY	$44.49 - $62.93 $2.35 Million - $3.32 Million	52,714 Added 286.93%	71,086 $4.4 Million
Q3 2023 Nov 09, 2023	BUY	$45.51 - $65.0 $160,377 - $229,060	3,524 Added 23.73%	18,372 $844,000
Q2 2023 Aug 11, 2023	SELL	$35.77 - $58.38 $291,239 - $475,329	-8,142 Reduced 35.42%	14,848 $853,000
Q1 2023 May 12, 2023	BUY	$27.99 - $37.92 $165,588 - $224,334	5,916 Added 34.65%	22,990 $862,000
Q4 2022 Feb 08, 2023	BUY	$27.93 - $31.27 $45,358 - $50,782	1,624 Added 10.51%	17,074 $478,000
Q3 2022 Nov 10, 2022	SELL	$27.56 - $37.75 $333,090 - $456,246	-12,086 Reduced 43.89%	15,450 $434,000
Q2 2022 Aug 10, 2022	SELL	$29.79 - $42.29 $10,515 - $14,928	-353 Reduced 1.27%	27,536 $958,000
Q1 2022 May 16, 2022	BUY	$22.96 - $36.45 $332,254 - $527,467	14,471 Added 107.85%	27,889 $1 Million
Q4 2021 Feb 14, 2022	BUY	$18.14 - $23.29 $75,426 - $96,839	4,158 Added 44.9%	13,418 $313,000
Q3 2021 Nov 15, 2021	SELL	$17.83 - $21.49 $385,609 - $464,764	-21,627 Reduced 70.02%	9,260 $176,000
Q2 2021 Aug 13, 2021	SELL	$17.11 - $20.92 $189,168 - $231,291	-11,056 Reduced 26.36%	30,887 $623,000
Q1 2021 May 12, 2021	SELL	$17.21 - $20.65 $17,863 - $21,434	-1,038 Reduced 2.42%	41,943 $769,000
Q4 2020 Feb 11, 2021	BUY	$17.76 - $21.24 $460,516 - $550,753	25,930 Added 152.07%	42,981 $865,000
Q3 2020 Nov 12, 2020	SELL	$17.99 - $22.22 $332,653 - $410,870	-18,491 Reduced 52.03%	17,051 $320,000
Q2 2020 Jul 31, 2020	BUY	$14.25 - $22.46 $66,447 - $104,730	4,663 Added 15.1%	35,542 $798,000
Q1 2020 May 01, 2020	SELL	$12.66 - $20.08 $437,846 - $694,466	-34,585 Reduced 52.83%	30,879 $458,000
Q4 2019 Feb 14, 2020	BUY	$17.07 - $20.64 $34,071 - $41,197	1,996 Added 3.14%	65,464 $1.26 Million
Q3 2019 Nov 14, 2019	BUY	$19.12 - $22.62 $203,283 - $240,495	10,632 Added 20.12%	63,468 $1.26 Million
Q2 2019 Aug 14, 2019	BUY	$18.92 - $22.96 $191,281 - $232,125	10,110 Added 23.66%	52,836 $1.12 Million
Q1 2019 May 14, 2019	BUY	$19.46 - $25.28 $559,085 - $726,294	28,730 Added 205.27%	42,726 $873,000
Q4 2018 Feb 14, 2019	SELL	$17.72 - $22.51 $18,375 - $23,342	-1,037 Reduced 6.9%	13,996 $278,000
Q3 2018 Nov 14, 2018	BUY	$15.39 - $19.38 $181,571 - $228,645	11,798 Added 364.7%	15,033 $289,000
Q2 2018 Aug 14, 2018	SELL	$14.63 - $19.6 $54,306 - $72,755	-3,712 Reduced 53.43%	3,235 $49,000
Q1 2018 May 15, 2018	BUY	$17.23 - $20.35 $6,064 - $7,163	352 Added 5.34%	6,947 $131,000
Q4 2017 Feb 14, 2018	BUY	$17.76 - $19.75 $36,052 - $40,092	2,030 Added 44.47%	6,595 $127,000
Q3 2017 Nov 14, 2017	SELL	$14.73 - $17.99 $43,659 - $53,322	-2,964 Reduced 39.37%	4,565 $82,000
Q2 2017 Aug 14, 2017	SELL	N/A	-1,820 Reduced 19.47%	7,529 $134,000
Q1 2017 Nov 14, 2017	BUY	N/A	9,349	9,349 $136,000

Others Institutions Holding AMPH

# of Institutions

275

Shares Held

35.2M

Call Options Held

26.5K

Put Options Held

7.9K

View Full List

About Amphastar Pharmaceuticals, Inc.

Ticker AMPH
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,015,200
Market Cap $1.34B
Description
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-count...

More about AMPH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account